Meta banned our GLP-1 campaign six hours after launch. Not a warning. Not a request for documentation. Account restriction, ads paused, appeal required. We had not violated any explicit policy we could find. The ad copy did not mention weight loss. The landing page did not sell anything directly. And still, the ban came.
After running GLP-1 campaigns on Meta for multiple clients, we now understand what triggers these bans and how to reverse them. The root cause sits in Meta's automated enforcement system and its treatment of GLP-1 medications as restricted health products. Here is what we learned and how we recovered.
Why Meta Flags GLP-1 Ads
Meta classifies GLP-1 receptor agonists as prescription drug products under its Restricted Content policy for Healthcare and Medical Services. This triggers three enforcement mechanisms simultaneously.
Automated keyword scanning. Meta's system scans for drug names in ad copy, headlines, and landing pages. Semaglutide, Tirzepatide, Ozempic, Wegovy, Mounjaro, and Rybelsus are all on the automated flag list. Even mentioning these terms in informational content triggers the restriction. Our ad that was banned used the phrase 'GLP-1 therapies' and never named a specific drug. The system flagged it anyway.
Landing page deep crawl. Meta's crawler goes beyond the landing page. It follows internal links and scans for prescription language, pharmacy terminology, and any implication of direct-to-consumer medication sales. If your blog about GLP-1 therapies links to a compounding pharmacy website, Meta treats the entire domain as a restricted health advertiser.
Account history and advertiser category. If your Facebook ad account has ever run ads in the health or pharmaceutical category, Meta applies heightened scrutiny to all future campaigns. Advertiser category is sticky. Once Meta classifies you as a health advertiser, every campaign undergoes additional compliance review.
The FDA Framework Behind Meta's Enforcement
Meta's policy is shaped by FDA regulation. Under FDA Section 503A, compounding pharmacies may prepare GLP-1 medications for individual patients with valid prescriptions. Under FDA Section 503B, registered outsourcing facilities may compound GLP-1s at scale under cGMP requirements. Meta's enforcement system does not distinguish between 503A pharmacies, 503B facilities, and unlicensed sellers.
The Drug Supply Chain Security Act (DSCSA) adds another layer. Meta uses signals from the FDA's drug registration database to verify whether advertisers are legitimate pharmaceutical entities. If your pharmacy is not in the FDA's public registration database or if the data is outdated, Meta's trust score for your account drops.
This is where DSHEA 1994 also comes into play. While DSHEA primarily addresses dietary supplements, it establishes the regulatory boundary between supplements and drugs. GLP-1 receptor agonists are drugs, not supplements. Any GLP-1 ad that frames the product as a wellness supplement or uses supplement marketing language triggers both FDA and Meta enforcement.
How We Got the Ban Reversed
The reversal took 11 days and involved three separate appeal submissions. Here is what worked.
First appeal , identity verification
Meta requires advertiser identity verification for restricted health categories. We submitted the pharmacy's state board license, DEA registration, and a letter from the supervising pharmacist confirming the pharmacy compounds GLP-1s only for patients with valid prescriptions. The first appeal was rejected because Meta wanted documentation in a specific format we had not used.
Second appeal , compliance documentation
We resubmitted with a structured compliance packet. The packet included the pharmacy's FDA establishment registration confirming 503B status, the state board of pharmacy license with active verification link, a signed attestation that the pharmacy does not sell GLP-1 medications directly to consumers, and a breakdown of the landing page content confirming no direct sales.
We also included a short memo citing FDA guidance on compounding and explaining that the ad was informational, not promotional. Meta's review team accepted this on the second appeal.
Third appeal , BAV escalation
The second appeal restored the ad account but left the ads paused. We escalated through Meta's Business Appeals Verification (BAV) channel, submitting the same compliance packet with a cover letter explaining the account's history and compliance measures. Within 48 hours, the ads were reactivated.
What We Changed to Prevent Future Bans
After the reinstatement, we made structural changes to prevent the cycle from repeating.
Ad copy that passes. We stopped using any drug names in ad copy. Instead of 'Semaglutide compounding,' we use 'personalized metabolic health support.' Instead of 'GLP-1 therapy,' we use 'provider-guided treatment plans.' This is not evasive. It accurately describes the service without triggering automated keyword flags.
Landing page architecture. We built a dedicated landing page that sits between the ad and the pharmacy website. The intermediate page explains the service, lists the pharmacy's credentials, and includes a consultation form. The actual pharmacy website is one click deeper. Meta's crawler sees a compliance page, not a storefront.
Verified ad account status. We completed Meta's full advertiser identity verification including business address confirmation, phone verification, and document upload. Verified accounts receive priority review and are less likely to be flagged by automated enforcement.
Pre-approval for restricted categories. Meta offers a pre-approval path for healthcare advertisers. We submitted our compliance documentation through Meta's Business Support before launching any new campaigns. Pre-approved accounts bypass the automated review queue for subsequent campaigns.
Since implementing these changes, the pharmacy client has launched four GLP-1 campaigns on Meta without a single restriction. The campaigns generate qualified consultation requests at a cost per lead that beats their Google campaigns by 18 percent. Meta's audience targeting for health-interested users is the most precise in the industry, and once compliance is locked in, the platform performs.
Dealing with GLP-1 ad bans on Meta is part of what we do every day. If your ads are paused or your account is restricted, we can help you build the compliance framework Meta reviewers accept.
Book a call → calendly.com/custodio-2/30min